Last reviewed · How we verify
Amlodipin
At a glance
| Generic name | Amlodipin |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Target | Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Angina pectoris
- Cerebrovascular accident
- Hypertensive disorder
- Myocardial Infarction Prevention
- Primary Prevention of Coronary Heart Disease
- Prinzmetal angina
Common side effects
- Edema
- Cough
- Headache
- Dizziness
- Flushing
- Nausea
- Asthenia
- Fatigue
- Dry mouth
- Abdominal pain
- Dyspepsia
- Insomnia
Serious adverse events
- Angioedema
- Neutropenia
- Esophagitis
Key clinical trials
- Effect of Atorvastatin on Carotid Intima Media Thickness (PHASE4)
- Fixed-Free HTN Trial (PHASE4)
- Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine (PHASE3)
- Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject (PHASE1)
- Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use (PHASE1)
- Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions (PHASE1)
- Intensive Vasodilator Therapy in Patients With Essential Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipin CI brief — competitive landscape report
- Amlodipin updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI